SO
GLUE icon

STRS Ohio’s Monte Rosa Therapeutics GLUE Stock Holding History

STRS Ohio’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.2K Sell
2,900
-39,800
-93% -$752K ﹤0.01% 1962
2026
Q1 		$702K Buy
42,700
+6,600
+18% +$126K ﹤0.01% 846
2025
Q4 		$566K Buy
+36,100
New +$486K ﹤0.01% 974
2024
Q4 		– Sell
-3,100
Closed -$16.4K – 1945
2024
Q3 		$16.4K Hold
3,100
– – ﹤0.01% 1904
2024
Q2 		$11.6K Hold
3,100
– – ﹤0.01% 1916
2024
Q1 		$21K Buy
+3,100
New +$18.4K ﹤0.01% 1849
2022
Q2 		– Sell
-6,800
Closed -$95K – 2135
2022
Q1 		$95K Buy
6,800
+4,100
+152% +$56.9K ﹤0.01% 1855
2021
Q4 		$55K Hold
2,700
– – ﹤0.01% 1992
2021
Q3 		$60K Buy
+2,700
New +$77.4K ﹤0.01% 2040

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

STRS Ohio's GLUE Position: Q2 2026 in Review

STRS Ohio reduced its Monte Rosa Therapeutics (GLUE) stake by 93% in Q2 2026, selling an estimated $752K and leaving 2,900 shares worth $70.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1962.

STRS Ohio first reported a position in GLUE in Q3 2021 and has held it in 9 quarters since. The position peaked at $702K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • STRS Ohio held 2,900 shares of Monte Rosa Therapeutics worth $70.2K as of Q2 2026.
  • STRS Ohio sold 39,800 Monte Rosa Therapeutics shares in Q2 2026, an estimated $752K.
  • Monte Rosa Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1962 holding.
  • STRS Ohio first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • STRS Ohio's Monte Rosa Therapeutics position peaked at $702K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.